For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Genpact Limited (G) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-10-07): Designation Gem · Gem Score +46 (−100…+100 Quality+Value blend) · Quality 72 · Value 28 · Sentiment -2 (timing only, not weighted) · Composite fair value $61.17 vs $37.32 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Genpact Limited
G NYSEGenpact Limited is a global professional services and technology company that helps enterprises transform and manage complex operations. Genpact Limited provides digital transformation, business process management, data and analytics, technology consulting, and artificial intelligence services to clients across industries including financial services, consumer and healthcare, and high tech and manufacturing. Its offerings cover functions such as finance and accounting, procurement, supply chain, human resources, sales, and commercial operations, supporting organizations that rely on large-scale, data-driven workflows. The company serves businesses across India, the rest of Asia, North and Latin America, and Europe, positioning itself as an operations partner for multinational enterprises seeking process efficiency and technology-enabled execution. Founded in 1997 and headquartered in Hamilton, Bermuda, Genpact Limited remains focused on combining domain expertise with automation, analytics, and AI to support mission-critical business processes.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 3.13
Total Equity: $2.55B
Shares: 176,646,644
Total Debt: $1.55B
Cash: $853.84M
EBITDA: $820.87M
Total Debt: $1.55B
Cash: $853.84M
Revenue: $5.08B
Revenue: $5.08B
Revenue: $5.08B
Total Equity: $2.55B
Tax Rate: 24.3%
Equity: $2.55B
Total Debt: $1.55B
Cash: $853.84M
Current Liabilities: $1.60B
Long-Term Debt: $1.18B
Total Debt: $1.55B
Total Equity: $2.55B
Shares: 176,646,644
Shares: 176,646,644
CapEx: -$78.20M
Shares: 176,646,644
Stock Price: $38.02
Net Income: $552.49M
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 31, 2026 1:37am (37d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $4.0B | $4.4B | $4.5B | $4.8B | $5.1B |
| Cost of Revenue | $2.6B | $2.8B | $2.9B | $3.1B | $3.2B |
| Gross Profit | $1.4B | $1.5B | $1.6B | $1.7B | $1.8B |
| Operating Expenses | $923.0M | $1.0B | $939.8M | $988.0M | $1.1B |
| Operating Income | $509.0M | $502.2M | $630.9M | $702.1M | $750.2M |
| Net Income | $369.4M | $353.4M | $631.3M | $513.7M | $552.5M |
| EBITDA | $618.1M | $589.0M | $703.4M | $771.8M | $820.9M |
| EPS | $1.97 | $1.92 | $3.46 | $2.88 | $3.18 |
| EPS (Diluted) | $1.91 | $1.88 | $3.41 | $2.85 | $3.13 |
Balance Sheet (Annual)
Last updated: Aug 31, 2026 1:30am (37d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $899.5M | $646.8M | $583.7M | $648.2M | $853.8M |
| Total Current Assets | $1.9B | $1.8B | $1.9B | $2.1B | $2.7B |
| Total Assets | $5.0B | $4.6B | $4.8B | $5.0B | $5.8B |
| Current Liabilities | $1.3B | $1.1B | $1.3B | $963.7M | $1.6B |
| Long-Term Debt | $1.3B | $1.3B | $831.6M | $1.2B | $1.2B |
| Total Liabilities | $3.1B | $2.8B | $2.6B | $2.6B | $3.3B |
| Total Equity | $1.9B | $1.8B | $2.2B | $2.4B | $2.5B |
| Retained Earnings | $732.5M | $780.0M | $1.1B | $1.2B | $1.4B |
Cash Flow (Annual)
Last updated: Aug 31, 2026 1:49am (37d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $694.3M | $443.7M | $490.8M | $615.4M | $812.9M |
| Capital Expenditure | -$53.3M | -$50.6M | -$55.4M | -$82.8M | -$78.2M |
| Free Cash Flow | $640.9M | $393.1M | $435.4M | $532.7M | $734.7M |
| Acquisitions (net) | -$72.0M | $-33,000 | $-682,000 | $0 | -$80.4M |
| Net Debt Issued / (Repaid) | $316.0M | -$381.0M | -$19.9M | -$33.1M | $323.5M |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$298.2M | -$214.1M | -$225.5M | -$252.7M | — |
| Net Change in Cash | — | — | — | — | — |
Growth Trends (YoY %)
Last updated: Aug 31, 2026 1:37am (37d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +8.7% | +2.4% | +6.5% | +6.6% |
| Gross Profit Growth | +7.3% | +2.2% | +7.6% | +8.3% |
| Operating Income Growth | -1.3% | +25.6% | +11.3% | +6.9% |
| Net Income Growth | -4.3% | +78.6% | -18.6% | +7.6% |
| EBITDA Growth | -4.7% | +19.4% | +9.7% | +6.4% |
Dividend History (Last 20)
Last updated: Aug 26, 2026 3:34pm (42d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-10 | $0.19 | — | — | — |
| 2026-03-16 | $0.19 | — | — | — |
| 2025-09-11 | $0.17 | — | — | — |
| 2025-06-18 | $0.17 | — | — | — |
| 2025-03-11 | $0.17 | — | — | — |
| 2024-12-09 | $0.15 | — | — | — |
| 2024-09-11 | $0.15 | — | — | — |
| 2024-06-10 | $0.15 | — | — | — |
| 2024-03-08 | $0.15 | — | — | — |
| 2023-12-07 | $0.14 | — | — | — |
| 2023-09-07 | $0.14 | — | — | — |
| 2023-06-08 | $0.14 | — | — | — |
| 2023-03-09 | $0.14 | — | — | — |
| 2022-12-08 | $0.13 | — | — | — |
| 2022-09-08 | $0.13 | — | — | — |
| 2022-06-09 | $0.13 | — | — | — |
| 2022-03-09 | $0.13 | — | — | — |
| 2021-12-09 | $0.11 | — | — | — |
| 2021-09-09 | $0.11 | — | — | — |
| 2021-06-10 | $0.11 | — | — | — |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Computed 2026-10-04 02:02| Case | Growth | Margin | Fair value | vs price ($37.32) |
|---|---|---|---|---|
| Bull — recovery | +12% | 17.3% | $93.28 | +150% |
| Base — stabilizes | +8% | 15.0% | $71.79 | +92% |
| Bear — keeps slipping | +4% | 12.8% | $54.06 | +45% |
| Stress — last quarter repeats | +6% | 10.8% | $48.95 | +31% |
| Upside — a +1σ run of quarters (v2) | +11% | 11.7% | $61.98 | +66% |
| Stress — a −1σ run of quarters (v2) | +2% | 10.8% | $43.77 | +17% |
Narrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-09-05 00:52The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Looking at the raw numbers first: Genpact is delivering exactly what a mid-single-digit compounder should. Revenue moved from $1.21B (Q3 24) to $1.34B (Q2 26) — that's ~10.7% growth over seven quarters, roughly 6% annualized, and importantly the sequential prints are monotonically rising with one blip (Q4 25 seasonal). Net margins sit in a tight 10.6–11.4% band. Annual revenue $4.02B → $5.08B over four years (6.0% CAGR), operating income $509M → $750M (10.2% CAGR), so operating leverage is real — op margin expanded from 12.7% to 14.8%. FCF of $735M on a $6.27B market cap is a 11.7% FCF yield. At 11.9x earnings, 8.5x EV/EBITDA, and 1.38x EV/sales for a business generating 21.7% ROE and 17.5% ROIC, this is quantitatively cheap by any absolute IT services benchmark (Accenture ~22x, Cognizant ~15x, Infosys ~24x).
The synthesis' $68 fair value strikes me as aggressive but directionally right. A simpler check: apply a 15x multiple (still a discount to peers) to trailing $587M NI → $8.8B equity, ~$52/share. Or capitalize $735M FCF at 8% discount with 2% terminal growth → ~$12.2B enterprise value, ~$66/share after netting debt. The composite $61 sits between these; the "signal-adjusted" $68 feels like double-counting optimism. I'd anchor fair value at $52–58, still a 40–55% gap to $37.32. The thesis-evaluation score of -8 is the outlier here — it's overweighting an AI-disruption narrative that hasn't shown up in the numbers. If AI cannibalization were real, you'd see it in decelerating revenue, margin compression, or client churn. Instead margins are expanding and revenue is accelerating (Q2 26 YoY is 7.2% vs 5.8% a year earlier). The bear case is a prediction, not a diagnosis.
Where I'd push back on the bullish synthesis: the insider tape is genuinely unhelpful — six sales in August 2026 totaling ~56k shares against April awards suggests programmatic disposition, not conviction, but there's zero open-market buying either. The "earnings CAGR -6.5%" flag is a 2023 comp artifact ($631M NI included a tax benefit); normalized earnings CAGR is closer to +10%. The decelerating quarterly trend flag is wrong — Q2 26 at $1.34B is the highest print ever and YoY growth is re-accelerating. However, the contrarian argument that deserves airtime: Genpact's largest client concentration and India-heavy delivery model mean a genuine agentic-AI substitution wave (not gradual, but step-function in 2027–28) could compress the $2.5B+ of finance/accounting/procurement BPO revenue by 15–25% within 24 months, and the operating leverage that helped on the way up works viciously in reverse. That's the real bear case, not "insourcing" hand-wringing. It's a tail risk, not a base case, but it justifies *some* discount — perhaps a 14x P/E rather than 18x.
Where the data is thin: no segment-level revenue disclosure in the file to see whether Digital Operations is offsetting classic BPO decline, no bookings/backlog trajectory, no client concentration detail, and the 2026 quarters flagged as future-dated need verification (if these are real prints, the story is intact; if they're estimates mislabeled, the entire recent trajectory needs re-underwriting). The macro-headwinds tag matters — enterprise IT spend is soft, and Genpact's Q2 26 acceleration into that could be share gain or could be one large deal. I'd want to see it repeat before paying peer multiples.
Net: I agree with the synthesis direction (undervalued) but dissent on the magnitude. $68 assumes multiple re-rating AND growth acceleration AND no AI impairment — too many things going right. A $52–58 fair value gives you 40–55% upside with a defensible 14–16x multiple on flat-to-modestly-growing earnings. The thesis-evaluation "-8" score is wrong because it's weighting narrative risk equally with observed cash generation; you can't ignore $735M of FCF because someone might disrupt it later. Starter position at $37 makes sense; the FCF yield alone (11.7%) pays you to wait, the 1.9% dividend is covered 10x by FCF, and net debt of $696M against $813M operating cash flow is trivial leverage. This is a boring compounder priced like it's melting, and the melting isn't in the numbers yet.
GPT Reading
Genpact looks cheaper than it deserves to be, but not nearly as mispriced as the $60-68 valuation outputs suggest. The core numbers say this is a solid, durable services franchise growing faster than a “melting ice cube” label would imply. Revenue has moved from $4.02B in 2021 to $5.08B in 2025, a 6%+ CAGR, and the quarterly run-rate has stepped up again to $1.34B in 2026-06 from $1.25B a year earlier. Net income has been remarkably steady in the $130M-$148M quarterly band, with net margins consistently around 10.6%-11.4%. That stability matters: this is not a business already showing AI-driven collapse in demand or pricing. On current numbers, the stock trades at about 11.9x earnings, 8.5x EV/EBITDA, and roughly 1.3x sales for a company generating ROIC of 17.5% and free cash flow of $734.7M. That is a low multiple for a business with decent growth, high cash conversion, and no obvious balance sheet stress.
What stands out most is the cash profile. 2025 operating cash flow of $812.9M against $552.5M of net income is excellent conversion, and capex is only $78.2M, leaving FCF at $734.7M. Against a $6.27B market cap, that is an FCF yield of roughly 11.7%, which is plainly attractive if the business is even flat, let alone growing mid-single digits. Net debt is only about $700M after offsetting $1.55B debt with $853.8M cash, so enterprise value is not being distorted by leverage. The market is acting as if either margins are about to roll over hard or revenue growth will stall. But the recent data do not show that. Quarterly revenue has risen from $1.21B in 2025-03 to $1.34B in 2026-06, while net margins have stayed anchored near 11%. For an outsourcing/IT services company, that combination usually earns at least a market multiple, not a discount one.
I do think the bullish models overreach by treating Genpact like a simple compounding annuity. The annual earnings history is less clean than the current P/E makes it look. Net income was $631.3M in 2023, then dropped to $513.7M in 2024 before recovering to $552.5M in 2025, so the five-year earnings CAGR is actually negative despite revenue growth. That suggests some combination of tax effects, margin variability, or below-the-line noise that makes a straight earnings multiple less bulletproof than the screen implies. And while operating margin improved to 14.8% in 2025 from 11.5% in 2022, the quarterly net margin pattern since late 2024 has been basically flat, not expanding. So I would not underwrite a dramatic rerating to premium IT services multiples. My read is simpler: this is a quality but unexciting operator priced a bit too cheaply, not a hidden compounder the market has missed by 80%.
The best bear case is that the market is correctly discounting a business whose “steady” numbers lag a structural threat. If AI reduces labor intensity in back-office workflows, Genpact’s legacy outsourcing base could face lower volumes, lower pricing, or both. In that framework, today’s 10%-11% net margins are a peak sustained by contracts that will reprice down over time. The decelerating quarterly trend note also deserves respect; the revenue increase from $1.29B in 2025-09 to $1.34B in 2026-06 is still growth, but not acceleration. Insider activity is all sales in the latest cluster, and while the sizes are not alarming, there are no offsetting open-market buys to signal conviction. A smart bear would also point out that if this were truly a superior business, the market would not leave it at 1.3x sales and 12x earnings without reason; IT services investors have seen too many “cheap for a reason” labor-arbitrage names. I weigh that differently because the feared deterioration is not yet in the reported numbers: revenue is still growing mid-single digits, free cash flow is robust, leverage is manageable, and margins are not cracking.
What would change my mind is straightforward. If the next two quarters show revenue slipping back toward $1.28B-$1.30B while net margin falls below 10%, that would validate the structural bear case and make even 12x earnings too high. Likewise, if annual free cash flow drops materially below $600M without an acquisition explanation, the cash-yield support weakens fast. On the other hand, if Genpact can sustain 5%-7% top-line growth with quarterly net income staying in the $140M+ range and demonstrate that AI is supporting mix and productivity rather than cannibalizing demand, the stock should not sit at 11x-12x earnings. In that scenario, I would expect a more reasonable range around 14x-15x earnings, which supports a price in the mid-$40s rather than the high $30s.
Grok Reading
The raw numbers describe a cash machine the market has marked down as if it were already broken. Genpact just put up $5.08B in 2025 revenue, up from $4.77B and $4.48B the two years prior, a clean 6.5% revenue CAGR that has not stalled: the last four quarters run $1.29B–$1.34B with the June 2026 print at $1.34B, still +6–7% year-on-year. Net income of $552.5M and a trailing net margin of 10.9% sit inside a narrow 10.6–11.4% band for eight straight quarters; operating margin is 14.8% and gross margin 36%. Free cash flow of $734.7M against only $78M of capex is the standout—FCF conversion above 130% of net income and an FCF yield of roughly 11.7% on the $6.27B market cap. Balance sheet is unremarkable and solvent: $1.55B debt, $854M cash, net debt under $700M, debt-to-equity 0.61, current ratio 1.66. ROE at 21.7% and ROIC at 17.5% are high-quality returns for a services firm. At 11.9x earnings, 1.3x sales and 8.5x EV/EBITDA the stock is priced as if growth is zero and margins are about to collapse; the composite fair-value work pointing to the low-to-mid $60s is directionally consistent with a business that already earns enough to justify a floor well above $37 even with no growth.
The earnings CAGR of –6.5% is the one ugly print and it is mostly base-effect noise: 2023 net income of $631M was an outlier versus the $350–550M range around it, and recent earnings are actually up 7.6% year-on-year. Revenue confidence is labeled “decelerating,” yet absolute dollars keep grinding higher and the mix has not yet shown margin compression. Insider activity is a string of open-market sales in August 2026 after April awards—classic post-vesting liquidity, not a panic signal, and classified neutral. The market narrative layer is correct that there is almost no story premium here; Genpact trades on macro caution about BPO longevity rather than on any cult or breakthrough claim. That absence of narrative is exactly why the discount exists, and why a re-rating does not require heroics—only evidence that the ice cube is not melting.
The strongest counter-argument is structural, not cyclical. A smart bear will say traditional labor-arbitrage outsourcing is being hollowed out by generative AI, client insourcing, and automation of the exact process work Genpact sells; at 12x the market is already generous if revenue growth slides to low-single digits and operating margins compress two to three points. The thesis-evaluation layer’s top bear weights (AI disruption accelerating, adverse mix/pricing pressure) are real risks, and the slight negative thesis score (–8) reflects that the bear mass edges the bull mass. Sticky enterprise relationships and the digital/AI pivot are the usual management retorts, but they remain unproven at scale in the numbers—we do not yet see acceleration above the 6–7% trend or margin expansion that would prove the pivot is working. I weigh the counter lower because the cash-flow statement still shows the opposite of a melting ice cube: FCF is rising fast (FCF CAGR ~30%), margins have held flat through eight quarters of AI hysteria, and the stock already embeds a permanent decline scenario that the trailing data simply do not support. Paying 12x for mid-single-digit growth plus 11%+ FCF yield leaves a wide margin of safety even if the bear is half right.
What flips me is concrete: two consecutive quarters of revenue growth under 3% with operating margin under 13%, or a full-year 2026 guide that abandons the mid-single-digit trajectory, would confirm structural decay and push me to fairly valued or worse at this price. Conversely, a print showing digital/AI-related work driving high-single-digit growth with stable-to-rising margins would force a sharper re-rating case and higher conviction.
Qwen Reading local experiment · off-panel
The number that jumps off the page and that I think the "Market Headwinds" model is trying to talk you out of is the free cash flow. $734.7M of FCF on a $6.26B market cap is an 11.7% yield, and the FCF CAGR of 29.9% tells you this isn't a one-year fluke — the business is getting more cash-efficient every year while revenue grows 6.5% CAGR from $4.02B in 2021 to $5.08B in 2025. Operating cash flow of $812.9M against capex of just $78.2M means this is a genuinely capital-light machine. ROIC of 17.5% and ROE of 21.7% are not the returns of a business whose model is being "structurally obsoleted within five years" as the top bear thesis claims. If generative AI were actually cannibalizing Genpact's labor-arbitrage revenue, I would expect to see revenue flat or declining and FCF compressing. Instead, quarterly revenue has climbed from $1.21B to $1.34B over the last eight quarters, and net margins have held in a tight 10.6–11.4% band. The data says the pivot to digital and AI-enabled services is working, not failing.
The "Thesis Evaluation" scoring this at -12 and the "Market Forces" model calling it a value trap are, in my view, overweighting a narrative risk that the financials have not yet confirmed. The 2023 net income spike to $631.3M (versus $353M in 2022 and $514M in 2024) is clearly a one-time item — probably a tax benefit or asset sale — and the "earnings CAGR of -6.5%" that the momentum module reports is an artifact of that distortion. Strip out 2023 and the earnings trajectory is $353M → $514M → $553M, which is growth, not decline. The recent earnings YoY of +7.6% is the honest number. Meanwhile, the Valuation Synthesis model's $51.62 fair value, which implies roughly 40% upside, is not outlandish: at 11.8x trailing earnings with 6.5% revenue growth and 14.5% FCF margin, a 14–15x forward multiple (appropriate for a mid-single-digit grower with 20%+ ROE) puts the stock at $44–$48, and the DCF's $51.62 is defensible if you believe in five years of 5–6% growth. The stock is trading below its no-growth floor, which means the market is paying you to hold a business that is, by every cash-flow metric, still compounding.
The strongest case against my read is the one the bear thesis makes with real force: Genpact is a $5B revenue business growing at 6.5% in a sector where the marginal buyer is increasingly an AI platform, not a BPO. The insider selling in August 2026 — roughly 56,000 shares across six transactions, about $2.1M at current prices, roughly double the 26,000 shares awarded in April — is modest but directionally consistent with insiders who see the ceiling. The "Revenue Confidence" flag noting deceleration in the quarterly trend is a legitimate yellow flag: the incremental revenue per quarter has been $40–50M, and if that tapers to $20–30M, the 6.5% CAGR becomes 3–4%, and the multiple compression the market is already applying (11.8x vs. sector medians of 15–18x) becomes rational rather than pessimistic. I weigh this differently because the FCF growth rate of 30% CAGR is the counter-evidence: even if revenue growth halves, the cost discipline and mix shift toward higher-margin digital work can sustain or grow cash generation. A business that grows FCF 30% a year is not a value trap; it is a value opportunity that the market is mislabeling because the revenue line looks "boring."
What would change my mind is a quarterly print where revenue growth drops below 3% YoY *and* FCF declines year-over-year for the first time in three years. That combination would confirm the AI-disruption thesis is no longer narrative but operational. A second trigger would be a guidance cut from management that explicitly references client attrition or pricing pressure in the core BPO book, as opposed to the usual "guidance-and-beat" cycle the narrative layer describes. A third would be a sector-wide de-rating event — if EXL, Wipro, or Infosys all drop 20%+ on a single AI-related earnings miss, the 11.8x multiple on Genpact would no longer be a discount but a peer norm, and my "undervalued" call would need to be re-examined. None of those have happened yet, and the August insider sales, while worth watching, are within the range of routine post-vesting dispositions.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Revenue has climbed every year from 4.02B in 2021 to 5.08B in 2025 (about 6% CAGR), with gross margin holding at 35-36% and operating margin expanding from 12.7% to 14.8%. Free cash flow reached 734.7M in 2025, the highest in the series, and OCF/NI of 1.32x plus accruals of -2.4% of assets indicate reported earnings are backed by real cash. Beneish M at -2.72 shows no manipulation flags; Altman Z at 2.98 (grey but near the safe cutoff) is consistent with a mature, moderately levered services firm. Capital allocation looks shareholder-friendly: diluted share count has fallen from 193.0M to 176.6M (-2.2% CAGR), buybacks run 245% of SBC, and SBC at 1.8% of revenue is modest for an IT services peer. The balance sheet is the softest spot - 1.20B liquid cash but -348M net debt means it is not a fortress, though 734M annual FCF makes the leverage easily serviceable. Insider tape is mildly negative in direction (7 sales, no open-market buys) but the dollar amounts are small (~2M total) and look like routine executive liquidity, not a red flag.
Verify before trusting this (4)
- Customer concentration and top-10 client revenue share in 10-K
- Composition of net debt - maturity schedule and any near-term refinancing needs
- Segment mix between Digital Operations and Data-Tech-AI to gauge growth quality
- Whether the 2023 net income spike (631M) contains one-time items
Price is $37.32 on a $6.27B cap. The composite FV of $61 and signal-adjusted $68 imply 65-83% upside, but I discount those - the DCF at $71.97 embeds mid-teens growth that the bear case (AI/insourcing pressure on BPO) directly threatens, so I would not underwrite it. The EPV floor of $39.23 is more honest: it says the current earnings power alone, with zero growth, is worth roughly today's price. That is a real anchor - you are paying nothing for growth in a business that has been quietly compounding, generating ~$735M FCF, and shrinking share count. Deserved value on a skeptical, quality-adjusted view sits in the $44-50 range: EPV floor plus a modest credit for the Strong quality grade, clean earnings, and buyback discipline, but haircut for BPO cycle/AI overhang. Versus $37.32 that is roughly 20-30% upside - meaningful margin of safety but not a fat-pitch dislocation. This is Modestly Cheap: the market is treating a durable compounder as a structurally impaired one, and even if it is only half-right the price still works.
Verify before trusting this (5)
- Organic constant-currency revenue growth trajectory and any guidance cut
- Digital/analytics/AI revenue mix and growth vs legacy BPO decline
- Bookings and TCV trends - leading indicator of insourcing risk
- Buyback pace and remaining authorization
- Segment margin trend to confirm mix shift is accretive
The tape is mildly risk-on but the market is only 1% off highs with a 25.8 PE and 4.77% 10y, so macro pressure on a 0.58-beta services name is negligible in either direction. There is no dominant narrative here: intensity is minimal, cult is low, and the archetype is steady-compounder, meaning Genpact simply does not attract flows the way an AI infrastructure or consumer story does. What sentiment does exist is bifurcated - a low-grade bearish overhang on the whole BPO cohort (automation, insourcing, client self-service) versus a slowly building 'agentic AI' repositioning narrative around new product launches like the Record-to-Report Suite.
Verify before trusting this (4)
- Whether the agentic AI product launches (R2R Suite) start showing up in analyst upgrades or target revisions
- Any large enterprise client insourcing announcement that would validate the bear narrative
- Peer BPO prints (Cognizant, WNS, Infosys BPM) - a cohort re-rating would drag G either way
- Volume/sponsorship on the next earnings reaction as a tell on whether narrative is shifting
Enterprise operations spend is still expanding, but its composition is rotating. Money is moving from labor-arbitrage seat count toward outcome-priced, automation-embedded process delivery. That rotation is exactly why the category grows 13% while a heritage-BPM-weighted participant grows 7%: the growth is accruing to whoever owns the automated layer, not the staffed one. Genpact sits on the right side of the client relationship — it is inside finance, procurement and supply-chain workflows, with the data and process context that agentic systems need — but on the wrong side of the pricing unit for a large legacy book. Higher rates keep client budgets cost-led rather than growth-led, which favors Genpact's efficiency pitch on volumes while pressuring price. The world therefore supports continued growth for this business and simultaneously caps it below category pace until the AI-native mix is large enough to set the company's growth rate.
When we made this prediction on Sep 5, 2026, G was $37.32. We expect it to be $46.00 by Mar 2027, and we consider it great value under $34.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Sep 5, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.
Post-Report Due Diligence NOTES
Evidence for a closer look, not a verdict — no score or designation on this page has been changed by it. Items marked material are ones where a conclusion above moves to the other side of the price.
adjusted_earnings
flips down 10%
cost_of_capital
flips up 10%
shares
flips up 25%